



W-13 PDF 10/01

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **September 2025**

Commission File Number: **001-36187**

**EVOGENE LTD.**

(Translation of Registrant's Name into English)

**13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_

## CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

[99.1 Evogene Investor Presentation.](#)

---

**Signature**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD.  
(Registrant)

Date: September 10, 2025

By: /s/ Yaron Eldad  
Yaron Eldad  
Chief Financial Officer

---



evogene

**REAL-WORLD  
INNOVATION**

AI-first discovery platform  
generating multi-parameter  
molecules

Sep 10, 2025

The image features a central graphic of a vertical capsule. The top half of the capsule is filled with a clear liquid and contains a glowing orange molecular structure. The bottom half is filled with a colorful, multi-layered substance resembling a cellular or molecular structure. The background is a dark, gradient grey.

## FORWARD LOOKING STATEMENT

This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd. (the "Company"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws, as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, pipeline, as well as our capabilities and technology.


Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, the current war between Israel and Hamas and any further adverse impact that it may have on economic activity in Israel due to the calling up of a large number of reserve soldiers or the incurrence of debt to pay for the high cost of the war, and any accompanying future uncertainties for the security of the Company's operations in southern Israel, as well as those additional factors described in greater detail in Evogene's Annual Report on Form 20-F and in other reports Evogene files with and furnishes to the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract or commitment relating thereto or to the securities of the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.





**WE CALL IT: REAL-WORLD INNOVATION**





## EVOGENE PIONEERS REAL-WORLD INNOVATION

Using a proprietary generative AI engine, we design highly potent and novel small molecules, optimized across multiple-parameters, for the pharmaceutical and ag-chemical industries



## OUR STORY IN 3 SENTENCES

### GEN AI ENGINE

Design of small molecules with high probability of success



### REVOLUTIONIZING AG

Proven results with strategic collaborations




### PIONEERING IN PHARMA

Differentiated tech offering that fits market demand



# THE DISCOVERY & OPTIMIZATION CHALLENGE

DESIGN THE RIGHT CANDIDATES TO REACH THE MARKET



**LESS THAN  
10% OF  
MOLECULES  
TESTED IN  
CLINICAL TRIALS  
MAKE IT TO  
MARKET**



Discovery &  
optimization are the  
critical stages for  
increasing market  
success probability

## THE MULTI-PARAMETER OPTIMIZATION CHALLENGE

Creating a molecule that will succeed through all development phases requires balancing in advance multiple, often competing, parameters

### THE CHALLENGE FOR TRADITIONAL METHODS:

- Optimization typically limited to a small number of parameters
- Cannot address multiple-parameters simultaneously
- Requires lengthy, resource-intensive iterative cycles



INTRODUCING CHEMPASS AI:  
**A MULTI-PARAMETER DESIGN  
ENGINE FOR REAL-WORLD  
INNOVATION**



**MULTI-PARAMETER OPTIMIZATION**

Optimizes multiple-parameters simultaneously, adapted to project specific chemical, biological, and physical constraints, increasing probability of success

**NOVEL MOLECULAR STRUCTURES**

Based on 388 molecules, expanding far beyond traditional libraries, tapping into one of the largest searchable chemical universes

**HIGHLY POTENT**

AI-first designed molecules optimized through targeted experimental validation

## CHEMPASS AI: A MULTI-PARAMETER DESIGN ENGINE FOR REAL-WORLD INNOVATION

### CHEMPASS AI TRANSFORMS TRADITIONAL METHODS:

- Optimization of diverse product specific parameters
- Addresses multiple constraints simultaneously
- Minimizes lengthy, resource-intensive iterative cycles





**Making  
breakthroughs  
in life sciences  
smarter and  
faster**



13 evogene

## GOOGLE CLOUD x EVOGENE

### BREAKING NEW GROUND IN AI-FIRST MOLECULE DESIGN

#### TRANSFORMATIVE PARTNERSHIP

Combining Evogene's proprietary AI foundation model, with Google Cloud's world-class infrastructure to scale revolutionary molecular discovery

#### ACCELERATED INNOVATION

Google's infrastructure enabled efficient use of a massive dataset starting with millions and ultimately reaching a training set of approximately 38 billion molecular structures

#### 3x IMPROVED ACCURACY


Optimization across multiple-parameters reached 90% precision (vs. 29% in traditional GPT AI-model)

*"We're pleased to collaborate with Evogene's innovation in AI-powered molecule design. Their progress with ChemPass AI highlights the strength of pairing advanced AI infrastructure with deep scientific insight. We look forward to seeing the impact of this new model in drug discovery and agriculture."*


**BOAZ MAOZ, MANAGING DIRECTOR, GOOGLE CLOUD ISRAEL**



# CHEMPASS AI FOUNDED BY PROPRIETARY TECHNOLOGY BOOSTING PROBABILITY OF SUCCESS



## DELIVERING REAL-WORLD INNOVATION THROUGH TWO STRATEGIC MARKET DIVISIONS



## OUR STORY IN 3 SENTENCES

### GEN AI ENGINE

Design of small molecules with high probability of success



### REVOLUTIONIZING AG

Proven results with strategic collaborations



### PIONEERING IN PHARMA

Differentiated tech offering that fits market demand



## A GROWING MARKET WITH PLENTY OF ROOM FOR INNOVATION

- 1** Increase of pest resistance  
& regulatory requirements
- 2** Urgent need for new  
Modes of Action (MoAs)
- 3** Decreased rate in discovery  
of new pesticides due to lack  
of innovation



**\$43.3B**  
BROAD SPECTRUM  
HERBICIDES<sup>1</sup>

**\$22.2B**  
FUNGICIDES FOR  
MAJOR DISEASES<sup>2</sup>

**\$22.3B**  
BROAD SPECTRUM  
INSECTICIDES<sup>3</sup>





## STRATEGIC COLLABORATIONS



*"Bringing together AgPlenus' expertise with Bayer's CropKey approach to crop protection innovation will help accelerate the delivery of essential, sustainable, and affordable solutions to farmers and set a new benchmark in the industry."*

**Rachel Rama, Head of Small Molecules,  
Crop Science division**



nontreated treated

### Development of new sustainable Mode-of-Action broad spectrum, herbicide

Demonstrated high weed control efficacy and good tolerance in corn



*"The collaboration with AgPlenus has accelerated the identification of a class of herbicide chemistry that targets a new mode-of-action for weed control, something the industry has been lacking for decades."*

**Vid Hegde, Former VP of Crop  
Protection Discovery and Development**



Treated nontreated

### Development of novel herbicides


Demonstrated weed growth reduction in post emergence application

## INTERNAL PIPELINE WHEAT BLOTCH

### DISRUPTING A \$1.2B PROBLEM AT RECORD SPEED

- 70% of EU fungicide usage in wheat is for Wheat Blotch<sup>1</sup>
- EU market alone >\$1.2B annually<sup>1</sup>
- Widespread resistance to current top products ('Strobilurins') with 2024 sales of \$4.59B<sup>2</sup>

## APTF-4 PRESENTS STRONG POTENTIAL FOR REAL-WORLD INNOVATION



- Shows clear concentration-dependent antifungal efficacy
- Ongoing optimization to enhance potency
- 18 months from target to optimized hit

## OUR STORY IN 3 SENTENCES

### GEN AI ENGINE

Design of small molecules with high probability of success



### REVOLUTIONIZING AG

Proven results with strategic collaborations




### PIONEERING IN PHARMA

Differentiated tech offering that fits market demand






## GROWING OPPORTUNITY IN AI-DRUG DISCOVERY




## THE DISCOVERY AND OPTIMIZATION CHALLENGE


DEVELOPING CANDIDATES THAT WILL REACH THE MARKET



## CHEMPASS AI: DRIVING HIGHER CUMULATIVE PROBABILITY OF SUCCESS



## THE KEY FOR SUCCESS –STRATEGIC PARTNERSHIPS / INTERNAL EXPERTISE TAILORED TO EACH CHALLENGE & OPTIMIZED FOR SUCCESS



## SHOWCASING SYSTEM CAPABILITIES: MOLECULAR GLUE CASE STUDY

### **PARTNERSHIP WITH LEADING BIOTECH**


To develop first-in-class molecular glue therapeutics

### **NOVEL TARGET:**

Protein-protein interaction, considered highly challenging

### **CHEMPASS AI GENERATED 150 MOLECULES WITH PROMISING RESULTS**

- 100% novelty (not in DBs or patents)
- Synthesizability confirmed
- 93% uniqueness
- 92% validity (chemically viable)
- 6x improvement in binding prediction accuracy



MORE REAL-WORLD INNOVATION IN AG AND PHARMA  
**MEANS A BETTER WORLD FOR ALL**



**REAL-WORLD INNOVATION**

Unique technology to create novel small molecules

**AI-FIRST, FROM HIT TO LEAD**

Integrating proprietary technology across the entire discovery pipeline

**HIGHER PROBABILITY OF SUCCESS**

90% of molecules generated meet all predefined parameters

evogene  
Real-world innovation

**MULTI-PARAMETER OPTIMIZATION**

Balancing ~20 constraints simultaneously using ChemPass AI

**UNLIMITED INNOVATION**

Based on ~38B molecule structures

**PROVEN IN AG PIONEERING IN PHARMA**

Real-world impact where it matters most

evOgene



Creating  
**REAL-WORLD  
INNOVATION**  
for a better future